GSK Acquires Argentine Generics Firm for $253 Million

GlaxoSmithKline (GSK; London) says it has acquired Laboratorios Phoenix (Buenos Aires), a leading Argentine pharmaceutical business, for a cash consideration of about $253 million, to accelerate sales growth and further extend its pharmaceutical portfolio in Argentina and the Latin America region. Phoenix is focused on the development, manufacturing, and sale of branded generic products. GSK will gain access to a broad portfolio of branded generic pharmaceutical products covering therapeutic areas including cardiovascular, gastroenterology, metabolic and urology...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers